Details for New Drug Application (NDA): 211897
✉ Email this page to a colleague
The generic ingredient in APREMILAST is apremilast. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.
Summary for 211897
| Tradename: | APREMILAST |
| Applicant: | Teva Pharms Usa Inc |
| Ingredient: | apremilast |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Aug 18, 2022 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
| Approval Date: | Aug 18, 2022 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 30MG | ||||
| Approval Date: | Aug 18, 2022 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
